EU (CEP) submissions have been completed for Atorvastatin Calcium Trihydrate, Finasteride and Dapagliflozin Propylene Glycol

We're pleased to share that EU (CEP) submissions have been completed for the following APIs:
Atorvastatin Calcium Trihydrate, Finasteride, and Dapagliflozin Propylene Glycol

CEP submission is an important step in enabling smoother regulatory pathways for partners targeting European markets. It reflects our continued focus on quality systems, regulatory preparedness, and portfolio readiness, not just product availability.

For us, a portfolio is more than a list of molecules. It’s about supporting partners with confidence, clarity, and compliance at every stage of development. If you’re evaluating options for EU-focused programs and would like to understand portfolio alignment, formulation alignments, or next steps, we are happy to connect.
Please write to us [email protected]